MedPath

Effect of Shilajit Rasayana compound in Diabetic Nerve Damage

Phase 2
Completed
Conditions
Health Condition 1: null- Diabetic Distal Symmetric Poly Neuropathy
Registration Number
CTRI/2012/06/002712
Lead Sponsor
Institute for Post Graduate Teaching Research in Ayurveda
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Metabolically stable Type 2 diabetic patients with symptomatic diabetic sensorimotorpolyneuropathy (DSPN)

Patients of either sex between the age group 18â??80 years

Exclusion Criteria

1.Patients with other metabolic and endocrinal disorders.

2.Patients with non-diabetic neuropathies

3.Patients suffering from infectious diseases.

4.Patients with non-healing ulcer/ulcers.

5.Patients with Disabling Diabetic Polyneuropathy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Agnibala, Rogabala, and Chetasbala,Quality Of Life(WHO QoL) â?? BREF20, Biothesiometer for quantitative vibration assessment, Michigan Neuropathy Screening Instrument score (MNSI)and Modified Toronto Clinical Neuropathy ScoreTimepoint: 12 weeks (90)
Secondary Outcome Measures
NameTimeMethod
HBA1cTimepoint: 90days
© Copyright 2025. All Rights Reserved by MedPath